Mycophenolate Mofetil Monotherapy in Liver Transplantation: 5-year Follow-up of a Prospective Randomized Trial.
Schmeding M, Kiessling A, et al.Transplantation. 92(8): 923-929, 2011.
Aims
To evaluate the long term effect of mycophenolate mofetil monotherapy after liver transplantation.
Interventions
Continuing calcineurin inhibitor (CNI) standard therapy versus converting CNI to mycophenolate mofetil (MMF) monotherapy.
Participants
150 patients who received a liver transplant.
Outcomes
The primary endpoint was incidence of biopsy-proven acute and chronic rejection. Other outcomes included renal function measured as glomerular filtration rate, 5 years survival, infectious, cardiovascular, neurological and gastrointestinal complications, diabetes and malignancy development.
Follow-up
5 years
CET Conclusions
In this 5 year follow up no significant difference was noted in the incidence of acute rejection. No differences were noted in other outcomes but there was a significant improvement in renal function in patients with renal insufficiency after they had been switched to MMF monotherapy.
Data analysis
Per protocol analysis
Trial registration
Not reported